CGEM
insider transactionsCullinan Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-90.5K
0 buy · 90.5K sell
Net value · 365d
-$1.3M
$0 in · $1.3M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
17
0 buy · 90.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
25.3K sh
Own New
-
Grant·A
Director
$0
25.3K sh
Own New
-
Grant·A
Director
$0
25.3K sh
Own New
-
Grant·A
Director
$0
25.3K sh
Own New
-
Grant·A
Director
$0
21.8K sh
Own New
-
Grant·A
Director
$0
21.8K sh
Own New
-
Exercise·M
Chief Scientific Officer · 10b5-1
$0
4.0K sh
Own +4%
-
Sell·S
Chief Scientific Officer · 10b5-1
$3.1K
200 sh · $15.58
Own -0%
-
Sell·S
Chief Scientific Officer · 10b5-1
$113.9K
7.8K sh · $14.60
Own -4%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$17.2K
4.0K sh · $4.30
Own +2%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$0
4.0K sh
Own +3%
-
Sell·S
Chief Scientific Officer · 10b5-1
$125.4K
8.0K sh · $15.68
Own -4%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$17.2K
4.0K sh · $4.30
Own +2%
-
Sell·S
Chief Scientific Officer · 10b5-1
$25.2K
1.8K sh · $14.14
Own -1%
-
Sell·S
Chief Scientific Officer · 10b5-1
$52.1K
3.6K sh · $14.47
Own -2%
-
Sell·S
Chief Medical Officer
$66.3K
4.6K sh · $14.47
Own -3%
-
Sell·S
Chief Legal Officer
$52.1K
3.6K sh · $14.47
Own -3%
-
Sell·S
Nadim Ahmed KEY
President and CEO
$195.6K
13.5K sh · $14.47
Own -3%
-
Sell·S
Chief Scientific Officer · 10b5-1
$24.5K
1.8K sh · $13.99
Own -1%
-
Sell·S
Mary Kay Fenton KEY
Chief Financial Officer
$59.9K
4.4K sh · $13.62
Own -3%
-
Sell·S
Chief Medical Officer
$67.9K
5.0K sh · $13.62
Own -3%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$0
8.0K sh
Own +7%
-
Sell·S
Chief Scientific Officer · 10b5-1
$114.4K
8.0K sh · $14.30
Own -4%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$34.4K
8.0K sh · $4.30
Own +4%
-
Sell·S
Chief Scientific Officer · 10b5-1
$51.0K
3.7K sh · $13.62
Own -2%
-
Sell·S
Chief Legal Officer
$51.0K
3.7K sh · $13.62
Own -3%
-
Sell·S
Nadim Ahmed KEY
President and CEO
$223.1K
16.4K sh · $13.62
Own -4%
-
Grant·A
Chief Legal Officer
$0
230.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
300.0K sh
Own New
-
Grant·A
Chief Business Officer
$0
175.0K sh
Own New
-
Grant·A
Mary Kay Fenton KEY
Chief Financial Officer
$0
137.5K sh
Own New
-
Grant·A
Mary Kay Fenton KEY
Chief Financial Officer
$0
68.8K sh
Own +111%
-
Grant·A
Chief Scientific Officer
$0
115.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
57.5K sh
Own +45%
-
Grant·A
Nadim Ahmed KEY
President and CEO
$0
828.0K sh
Own New
-
Sell·S
Chief Scientific Officer
$5.0K
416 sh · $12.03
Own -0%
-
Sell·S
Chief Scientific Officer · 10b5-1
$49.2K
4.0K sh · $12.30
Own -3%
-
Grant·A
Mary Kay Fenton KEY
Chief Financial Officer
$175
27 sh · $6.49
Own +0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Anthony Rosenberg | Grant A | 25.3K | $0 |
| Jun 16, 2026 | David D. Meek | Grant A | 25.3K | $0 |
| Jun 16, 2026 | Stephen W Webster | Grant A | 25.3K | $0 |
| Jun 16, 2026 | Mary Thistle | Grant A | 25.3K | $0 |
| Jun 16, 2026 | Mittie Doyle | Grant A | 21.8K | $0 |
| Jun 16, 2026 | Andrew R Allen | Grant A | 21.8K | $0 |
| May 5, 2026 | Jennifer Michaelson 10b5-1 | Exercise M | 4.0K | $0 |
| May 5, 2026 | Jennifer Michaelson 10b5-1 | Sell S | 200 | $3.1K |
| May 5, 2026 | Jennifer Michaelson 10b5-1 | Sell S | 7.8K | $113.9K |
| May 5, 2026 | Jennifer Michaelson 10b5-1 | Exercise M | 4.0K | $17.2K |
| Mar 5, 2026 | Jennifer Michaelson 10b5-1 | Exercise M | 4.0K | $0 |
| Mar 5, 2026 | Jennifer Michaelson 10b5-1 | Sell S | 8.0K | $125.4K |
| Mar 5, 2026 | Jennifer Michaelson 10b5-1 | Exercise M | 4.0K | $17.2K |
| Feb 25, 2026 | Jennifer Michaelson 10b5-1 | Sell S | 1.8K | $25.2K |
| Feb 24, 2026 | Jennifer Michaelson 10b5-1 | Sell S | 3.6K | $52.1K |
| Feb 24, 2026 | Jeffrey Alan Jones | Sell S | 4.6K | $66.3K |
| Feb 24, 2026 | Jacquelyn L Sumer | Sell S | 3.6K | $52.1K |
| Feb 24, 2026 | Nadim Ahmed KEY | Sell S | 13.5K | $195.6K |
| Feb 23, 2026 | Jennifer Michaelson 10b5-1 | Sell S | 1.8K | $24.5K |
| Feb 20, 2026 | Mary Kay Fenton KEY | Sell S | 4.4K | $59.9K |
| Feb 20, 2026 | Jeffrey Alan Jones | Sell S | 5.0K | $67.9K |
| Feb 20, 2026 | Jennifer Michaelson 10b5-1 | Exercise M | 8.0K | $0 |
| Feb 20, 2026 | Jennifer Michaelson 10b5-1 | Sell S | 8.0K | $114.4K |
| Feb 20, 2026 | Jennifer Michaelson 10b5-1 | Exercise M | 8.0K | $34.4K |
| Feb 20, 2026 | Jennifer Michaelson 10b5-1 | Sell S | 3.7K | $51.0K |
| Feb 20, 2026 | Jacquelyn L Sumer | Sell S | 3.7K | $51.0K |
| Feb 20, 2026 | Nadim Ahmed KEY | Sell S | 16.4K | $223.1K |
| Feb 18, 2026 | Jacquelyn L Sumer | Grant A | 230.0K | $0 |
| Feb 18, 2026 | Jeffrey Alan Jones | Grant A | 300.0K | $0 |
| Feb 18, 2026 | Corrine Savill | Grant A | 175.0K | $0 |
| Feb 18, 2026 | Mary Kay Fenton KEY | Grant A | 137.5K | $0 |
| Feb 18, 2026 | Mary Kay Fenton KEY | Grant A | 68.8K | $0 |
| Feb 18, 2026 | Jennifer Michaelson | Grant A | 115.0K | $0 |
| Feb 18, 2026 | Jennifer Michaelson | Grant A | 57.5K | $0 |
| Feb 18, 2026 | Nadim Ahmed KEY | Grant A | 828.0K | $0 |
| Feb 12, 2026 | Jennifer Michaelson | Sell S | 416 | $5.0K |
| Jan 22, 2026 | Jennifer Michaelson 10b5-1 | Sell S | 4.0K | $49.2K |
| Dec 31, 2025 | Mary Kay Fenton KEY | Grant A | 27 | $175 |
About CGEM insider trading
This page tracks insider transactions for Cullinan Therapeutics, Inc. (CGEM) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.